文献检索文档翻译深度研究

邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

不再提醒

EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy.

作者信息

Gavriilaki Eleni, Tzannou Ifigeneia, Batsis Ioannis, Tsonis Ioannis, Liga Maria, Gkirkas Konstantinos, Ximeri Maria, Dolgyras Panagiotis, Bampali Vasiliki, Evangelidis Paschalis, Bousiou Zoi, Vardi Anna, Demosthenous Christos, Stroggyli Eulampia, Bouzani Maria, Sagiadinou Eleftheria, Mallouri Despina, Tzenou Tatiana, Sotiropoulos Damianos, Gigantes Stavros, Anagnostopoulos Achilles, Karakasis Dimitrios, Papadaki Helen, Tsirigotis Panagiotis, Spyridonidis Alexandros, Vassilakopoulos Theodoros, Angelopoulou Maria, Sakellari Ioanna, Baltadakis Ioannis

机构信息

Hematology Department, Bone Marrow Transplantation Unit, G. Papanicolaou General Hospital of Thessaloniki, Thessaloniki, Greece.

Second Propedeutic Department of Internal Medicine, Hematology Unit, Hippocration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

出版信息

Blood Vessel Thromb Hemost. 2024 Aug 21;1(4):100025. doi: 10.1016/j.bvth.2024.100025. eCollection 2024 Dec.

DOI:10.1016/j.bvth.2024.100025

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12320397/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94e0/12320397/7d848c3ac5b7/BVTH_VTH-2024-000160-gr1.jpg

相似文献

[1]

EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy.

Blood Vessel Thromb Hemost. 2024-8-21

[2]

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy.

Blood Adv. 2025-1-28

[3]

Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.

Ann Hematol. 2024-3

[4]

Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients - A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts.

Arch Immunol Ther Exp (Warsz). 2024-1-1

[5]

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.

Blood Adv. 2021-9-14

[6]

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.

J Immunother Cancer. 2024-10-7

[7]

Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.

Cancers (Basel). 2023-11-16

[8]

Addition of Phosphorous and IL6 to m-EASIX Score Improves Detection of ICANS and CRS, as Well as CRS Progression.

Cancers (Basel). 2025-3-7

[9]

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.

Front Immunol. 2022

[10]

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients.

Int J Mol Sci. 2024-10-14

引用本文的文献

[1]

Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?

Cells. 2025-8-12

本文引用的文献

[1]

Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.

Cancers (Basel). 2023-11-16

[2]

ICANS prophylaxis: potentially transformative but elusive.

Blood Adv. 2023-11-14

[3]

IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy.

Ann Hematol. 2023-12

[4]

Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience.

Cancers (Basel). 2023-8-25

[5]

Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis.

Cancers (Basel). 2023-7-7

[6]

A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.

Front Immunol. 2023

[7]

How I treat refractory CRS and ICANS after CAR T-cell therapy.

Blood. 2023-5-18

[8]

Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma.

Blood Cancer J. 2023-1-5

[9]

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.

Front Immunol. 2022

[10]

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.

Blood Adv. 2021-9-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

推荐工具

医学文档翻译智能文献检索